Therefore, targeting the existing crosstalk between NF-κB and GLI1, despite SHh involvement, could be a potential successful strategy to treat advanced PCa that is characterized by activation of NF-κB and GLI1 signaling. The gene discussed is SHH; the disease is posterior cortical atrophy.